Xvivo Perfusion AB (publ) (XVIVO.ST)
SEK 465.0
(1.97%)
SEK 465.0
(1.97%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.19 Billion SEK | 26.69% |
| 2022 | 1.73 Billion SEK | 12.35% |
| 2021 | 1.54 Billion SEK | 34.1% |
| 2020 | 1.15 Billion SEK | 81.3% |
| 2019 | 634.48 Million SEK | 8.16% |
| 2018 | 586.61 Million SEK | 8.93% |
| 2017 | 538.54 Million SEK | 54.18% |
| 2016 | 349.29 Million SEK | 71.07% |
| 2015 | 204.18 Million SEK | 1.23% |
| 2014 | 201.7 Million SEK | 58.12% |
| 2013 | 127.56 Million SEK | 11.39% |
| 2012 | 114.51 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 2.27 Billion SEK | 0.86% |
| 2024 Q3 | 2.27 Billion SEK | 0.23% |
| 2024 Q1 | 2.25 Billion SEK | 2.65% |
| 2023 FY | 2.19 Billion SEK | 26.69% |
| 2023 Q3 | 2.23 Billion SEK | 25.09% |
| 2023 Q2 | 1.78 Billion SEK | 2.79% |
| 2023 Q4 | 2.19 Billion SEK | -1.85% |
| 2023 Q1 | 1.73 Billion SEK | 0.39% |
| 2022 Q4 | 1.73 Billion SEK | 5.58% |
| 2022 Q1 | 1.52 Billion SEK | -1.17% |
| 2022 FY | 1.73 Billion SEK | 12.35% |
| 2022 Q3 | 1.64 Billion SEK | 3.57% |
| 2022 Q2 | 1.58 Billion SEK | 3.95% |
| 2021 FY | 1.54 Billion SEK | 34.1% |
| 2021 Q1 | 1.16 Billion SEK | 1.55% |
| 2021 Q2 | 1.14 Billion SEK | -1.61% |
| 2021 Q3 | 1.14 Billion SEK | -0.43% |
| 2021 Q4 | 1.54 Billion SEK | 34.8% |
| 2020 Q2 | 620.4 Million SEK | -3.76% |
| 2020 Q3 | 1.11 Billion SEK | 80.38% |
| 2020 Q4 | 1.15 Billion SEK | 2.79% |
| 2020 Q1 | 644.66 Million SEK | 1.6% |
| 2020 FY | 1.15 Billion SEK | 81.3% |
| 2019 Q4 | 634.48 Million SEK | -3.46% |
| 2019 FY | 634.48 Million SEK | 8.16% |
| 2019 Q1 | 601.19 Million SEK | 2.49% |
| 2019 Q2 | 644.45 Million SEK | 7.19% |
| 2019 Q3 | 657.22 Million SEK | 1.98% |
| 2018 Q3 | 578.74 Million SEK | 0.36% |
| 2018 FY | 586.61 Million SEK | 8.93% |
| 2018 Q1 | 541.86 Million SEK | 0.62% |
| 2018 Q2 | 576.64 Million SEK | 6.42% |
| 2018 Q4 | 586.61 Million SEK | 1.36% |
| 2017 FY | 538.54 Million SEK | 54.18% |
| 2017 Q1 | 340.91 Million SEK | -2.4% |
| 2017 Q2 | 529.91 Million SEK | 55.44% |
| 2017 Q3 | 528.37 Million SEK | -0.29% |
| 2017 Q4 | 538.54 Million SEK | 1.92% |
| 2016 Q1 | 205.94 Million SEK | 0.86% |
| 2016 Q4 | 349.29 Million SEK | 0.72% |
| 2016 Q2 | 340.92 Million SEK | 65.54% |
| 2016 Q3 | 346.8 Million SEK | 1.72% |
| 2016 FY | 349.29 Million SEK | 71.07% |
| 2015 Q1 | 202.29 Million SEK | 0.29% |
| 2015 Q2 | 202.84 Million SEK | 0.27% |
| 2015 Q4 | 204.18 Million SEK | 1.51% |
| 2015 FY | 204.18 Million SEK | 1.23% |
| 2015 Q3 | 201.15 Million SEK | -0.83% |
| 2014 Q1 | 131.41 Million SEK | 3.02% |
| 2014 Q2 | 209.16 Million SEK | 59.16% |
| 2014 Q3 | 195.17 Million SEK | -6.69% |
| 2014 Q4 | 201.7 Million SEK | 3.34% |
| 2014 FY | 201.7 Million SEK | 58.12% |
| 2013 Q4 | 127.56 Million SEK | 8.18% |
| 2013 Q2 | 113.03 Million SEK | 3.8% |
| 2013 FY | 127.56 Million SEK | 11.39% |
| 2013 Q1 | 108.89 Million SEK | -4.91% |
| 2013 Q3 | 117.91 Million SEK | 4.32% |
| 2012 Q4 | 114.51 Million SEK | 0.0% |
| 2012 FY | 114.51 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Acarix AB (publ) | 62.88 Million SEK | -3391.526% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 33.211% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 33.211% |
| Arcoma AB | 81.96 Million SEK | -2578.816% |
| Bactiguard Holding AB (publ) | 682.87 Million SEK | -221.523% |
| BICO Group AB (publ) | 10.19 Billion SEK | 78.468% |
| Boule Diagnostics AB (publ) | 755.1 Million SEK | -190.771% |
| CellaVision AB (publ) | 928.71 Million SEK | -136.415% |
| Clinical Laserthermia Systems AB (publ) | 57.72 Million SEK | -3703.57% |
| Chordate Medical Holding AB (publ) | 21.95 Million SEK | -9900.288% |
| C-Rad AB (publ) | 404 Million SEK | -443.468% |
| Duearity AB (publ) | 15.14 Million SEK | -14398.224% |
| Dignitana AB (publ) | 44.83 Million SEK | -4797.528% |
| Episurf Medical AB (publ) | 104.3 Million SEK | -2005.092% |
| Getinge AB (publ) | 55.09 Billion SEK | 96.015% |
| Scandinavian Real Heart AB (Publ) | 102.63 Million SEK | -2039.174% |
| Iconovo AB (publ) | 128.07 Million SEK | -1614.251% |
| Integrum AB (publ) | 164.85 Million SEK | -1231.81% |
| Luxbright AB (publ) | 40.68 Million SEK | -5296.39% |
| Mentice AB (publ) | 322.52 Million SEK | -580.755% |
| OssDsign AB (publ) | 356.38 Million SEK | -516.071% |
| Paxman AB (publ) | 167.12 Million SEK | -1213.754% |
| Promimic AB (publ) | 92.87 Million SEK | -2264.05% |
| Qlife Holding AB (publ) | 39.04 Million SEK | -5523.139% |
| SciBase Holding AB (publ) | 64.33 Million SEK | -3312.831% |
| ScandiDos AB (publ) | 81.47 Million SEK | -2594.894% |
| Sectra AB (publ) | 3.21 Billion SEK | 31.621% |
| Sedana Medical AB (publ) | 1.01 Billion SEK | -116.518% |
| Senzime AB (publ) | 433.54 Million SEK | -406.436% |
| SpectraCure AB (publ) | 144.83 Million SEK | -1415.95% |
| Stille AB | 804.89 Million SEK | -172.783% |
| Vitrolife AB (publ) | 16.39 Billion SEK | 86.605% |